timothy R. franson, M.d.

Dr. Franson serves as Global Regulatory Affairs consulting expert for Housey Pharma and its subsidiary, Housey Healthcare, Inc. (HHI).  He advises on regulatory strategy and guidance for the Phase 2 Human Clinical Trials program for HP-211, Housey Pharma’s first-in-class, botanical anti-diabetic medicine.  Dr. Franson is a Principal at Faegre Drinker Consulting, a subsidiary of Faegre Drinker Biddle, where he leads their regulatory affairs practice.

Dr. Franson was formerly the Vice President of Global Regulatory Affairs at Eli Lilly & Company, one of the largest diabetes-focused pharmaceutical companies in the world.  Dr. Franson held increasing responsible positions at Eli Lilly from 1986 until 2008, including VP of Clinical Research and Regulatory Affairs-US from 1997 to 2003 and VP of Global Regulatory Affairs, a position he held for five years at Eli Lilly from 2003 through 2008.

Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization.  He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine.  He is board certified in Internal Medicine and Infectious Diseases, and Adjunct Professor of Medicine at Indiana University School of Medicine.  Click here for a complete listing of his biography.